This site is intended for UK healthcare professionals

 

Featured Videos #1

In recent years, there has been a switch to direct oral anticoagulants (DOACs) as first-line thrombosis prevention, with fewer people started on a vitamin K antagonist, such as warfarin. This has led to an increase in number of people taking anticoagulants and, therefore, an increased risk of intracranial and intracerebral haemorrhages and gastrointestinal bleeds. Listen to Richard Buka, Clinical Research Fellow Institute of Cardiovascular Sciences at the University of Birmingham, discuss the challenges clinical teams face in the reversal of these drugs. He explores the findings of recent trials of Andexanet alfa and considers how effective these drugs really are and what it means in practice.
The increasing survival rate of cancer patients along with the increase in the toxicity profile of treatments has resulted in a growing demand for specialist cardio-oncology care. Listen to Priya Reehal, Clinical Nurse Specialist at the Royal Brompton Hospital Centre of Excellence for Cardio-oncology, discuss her role, present the findings of a decade-long study into the number of patients referred for cancer therapy–related cardiac dysfunction, and explain why we need more cardio-oncology centres of excellence across the UK.
Federica Marelli-Berg takes a look at some common and not-so-common causes of myocarditis, and the clinical manifestations cardiologists should consider.
Dr Paul Foley and Prof Terry McCormack share the key changes in the new ESC guidance on atrial fibrillation, hypertension and arterial disease.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

Dr Sarah Birkhoelzer and Dr Aaron Henry discuss hot topics and late-breaking abstracts from across the congress.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

Jon Byrne and Madalina Garbi explore the latest guidelines and current practice around transcatheter valve interventions (including aortic valve implantation (TAVI), mitral regurgitation management and tricuspid valve repair) – which patients are suitable for these interventions, and how do they compare to traditional surgical approaches?

This webinar has been sponsored by A Menarini Pharmaceuticals Ireland and A. Menarini Farmaceutica Internazionale SRL who have had no input into the topics discussed or selection of speakers.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.